1. Home
  2. KGS vs ERAS Comparison

KGS vs ERAS Comparison

Compare KGS & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kodiak Gas Services Inc.

KGS

Kodiak Gas Services Inc.

HOLD

Current Price

$58.63

Market Cap

5.9B

Sector

N/A

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$14.81

Market Cap

6.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KGS
ERAS
Founded
2011
2018
Country
United States
United States
Employees
1300
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
6.3B
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
KGS
ERAS
Price
$58.63
$14.81
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
12
Target Price
$57.17
$14.25
AVG Volume (30 Days)
1.6M
4.1M
Earning Date
05-06-2026
05-08-2026
Dividend Yield
2.93%
N/A
EPS Growth
58.93
36.23
EPS
0.75
N/A
Revenue
N/A
N/A
Revenue This Year
$12.30
N/A
Revenue Next Year
$7.96
N/A
P/E Ratio
$77.71
N/A
Revenue Growth
N/A
N/A
52 Week Low
$32.55
$1.75
52 Week High
$77.68
$24.28

Technical Indicators

Market Signals
Indicator
KGS
ERAS
Relative Strength Index (RSI) 47.64 33.44
Support Level $54.65 $14.00
Resistance Level $65.80 $15.03
Average True Range (ATR) 2.42 1.06
MACD -0.21 -0.15
Stochastic Oscillator 40.08 11.79

Price Performance

Historical Comparison
KGS
ERAS

About KGS Kodiak Gas Services Inc.

Kodiak Gas Services Inc is an operator of contract compression infrastructure in the United States. The company manages its business through two operating segments: Contract Services and Other Services. Contract Services consists of operating company-owned and customer-owned compression, gas treating, and cooling infrastructure, pursuant to fixed-revenue contracts to enable the production and gathering of natural gas and oil. Other Services consist of a full range of contract services to support the ancillary needs of customers, including station construction, maintenance and overhaul, freight and crane charges, and other time and material-based offerings. Maximum revenue for the company is generated from its Contract Services segment.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: